Novo Still Has Work to Do to Build Investor Confidence, CEO Says

• Novo aims to build investor confidence by delivering good results quarter-by-quarter, following its laid-out plan.
• The company prioritizes internal growth but is open to M&A to fill strategic or scientific gaps, particularly in newer areas like cardiovascular, rather than obesity where it sees few attractive external assets.
• Novo is leveraging its direct-to-consumer model for prescription medications and is actively fighting against compounded drugs, noting reduced incentive for fake drugs due to more affordable prices.
• The CEO emphasizes a cultural transformation focused on customer obsession and competitiveness to continuously adapt to the changing external environment.

Novo CEO Mike Doustdar addresses investor disappointment regarding long-term sales aims, emphasizing a clear path forward through consistent results and strategic M&A. He highlights the company's focus on internal growth in obesity while actively seeking external assets in newer areas like cardiovascular, and discusses efforts against compounded drugs.